Cagrilintide: The Long-Acting Amylin Agonist Behind CagriSema

Most of the modern peptide weight-loss conversation still orbits GLP-1 and dual GIP/GLP-1 agonists. That framing is incomplete. Amylin is a separate satiety hormone co-secreted with insulin, and Novo Nordisk’s long-acting amylin analogue cagrilintide is now one of the clearest examples of multi-hormone obesity pharmacology moving from theory into large phase 3 programs.

Paired with semaglutide as CagriSema, cagrilintide produced some of the strongest mean weight-loss figures yet reported in a completed obesity phase 3 program. This article explains what cagrilintide is, how amylin signaling differs from GLP-1, and what REDEFINE 1 and REDEFINE 2 actually showed. Educational only — not medical advice, not dosing guidance, and not a recommendation to use any investigational product.

What Amylin Does

Amylin is a 37-amino-acid peptide released from pancreatic beta cells together with insulin after meals. Physiologically it:

• slows gastric emptying
• suppresses postprandial glucagon
• reduces meal size through central satiety circuits, especially in the area postrema and related brainstem pathways

Those effects are complementary to GLP-1 receptor agonism. GLP-1 drugs already slow emptying and suppress appetite through overlapping but non-identical neural and gut pathways. Adding a durable amylin signal is therefore a rational way to deepen caloric intake reduction without simply escalating one receptor harder.

Native amylin is a poor drug candidate. It aggregates, has a short half-life, and is awkward to formulate for weekly use. That is the engineering problem cagrilintide was built to solve.

What Cagrilintide Is

Cagrilintide is a long-acting synthetic amylin analogue developed by Novo Nordisk. In medicinal chemistry terms it is often described as a dual amylin and calcitonin receptor agonist (DACRA): it engages amylin receptor complexes formed by the calcitonin receptor plus receptor activity-modifying proteins (RAMPs), and also activates the calcitonin receptor itself.

According to the development paper by Kruse and colleagues in the Journal of Medicinal Chemistry (2021), the molecule was engineered from an amylin-like backbone with structural changes that improve solubility, reduce fibrillation risk, and support once-weekly subcutaneous dosing. The practical result is a peptide that can deliver sustained amylin-pathway exposure instead of the brief pulse produced by native hormone.

Cagrilintide is not FDA-approved as monotherapy as of this writing. Its highest-profile clinical path is combination development with semaglutide under the CagriSema program.

Monotherapy Signal: The Phase 2 Foundation

Before the combination story took over headlines, cagrilintide had to show that amylin agonism alone moves the scale.

In a multicenter, randomized, double-blind, placebo- and active-controlled phase 2 dose-finding trial published in The Lancet (Lau et al., 2021), once-weekly cagrilintide produced significant body-weight reductions versus placebo in adults with overweight or obesity and was generally well tolerated. That trial established dose-response, gastrointestinal tolerability patterns familiar from other satiety peptides, and the rationale for pairing cagrilintide with a GLP-1 agonist rather than treating it only as a niche add-on.

Phase 2 does not settle regulatory questions. It does answer the mechanistic one: durable amylin receptor agonism is a real weight-loss lever in humans.

CagriSema and the REDEFINE Phase 3 Program

CagriSema is coadministered once-weekly cagrilintide 2.4 mg plus semaglutide 2.4 mg. The phase 3 REDEFINE program tested that combination in two core populations.

REDEFINE 1: Overweight or obesity without diabetes

REDEFINE 1 was a 68-week, double-blind, placebo- and active-controlled phase 3a trial in adults with overweight or obesity and at least one weight-related comorbidity, without diabetes. Participants were randomized to CagriSema, semaglutide alone, cagrilintide alone, or placebo, all with lifestyle intervention.

Per the New England Journal of Medicine report by Garvey and colleagues and the concurrent American Diabetes Association summary:

• Mean body-weight change with CagriSema was approximately −20.4% at week 68 versus about −3.0% with placebo.
• Active comparators landed lower: roughly −14.9% with semaglutide 2.4 mg and −11.5% with cagrilintide 2.4 mg.
• On a treatment-adherence estimand, mean loss with CagriSema rose to about 22.7%, with a substantial fraction of participants reaching 25% or greater weight reduction.

Those head-to-head arms matter. They show that the combination outperformed either peptide alone under the same trial conditions, which is the pharmacologic argument for dual-pathway therapy rather than simply “more GLP-1.”

REDEFINE 2: Overweight or obesity with type 2 diabetes

REDEFINE 2 enrolled adults with overweight or obesity and type 2 diabetes. In the NEJM report by Davies and colleagues, mean body-weight change at 68 weeks was about −13.7% with CagriSema versus −3.4% with placebo. The adherence-oriented estimate was higher still, around 15.7%.

Weight loss in diabetes trials is typically harder than in non-diabetes obesity trials. The pattern here matches that historical gap while still showing a clear separation from placebo, plus substantial improvements in glycemic endpoints reported in the same program.

Why the Combination Makes Biological Sense

If you already understand GLP-1 receptor agonists, cagrilintide’s value is easier to place.

Semaglutide drives appetite reduction, slows gastric emptying, and improves glucose-dependent insulin secretion through GLP-1R. Cagrilintide adds amylin/calcitonin-receptor satiety signaling and further meal-size control. The pathways converge on reduced energy intake, but they are not redundant copies of one another.

That is why the field is moving from single-incretin drugs toward multi-agonist or multi-peptide regimens — the same broader trend that produced tirzepatide and retatrutide. CagriSema is different in architecture: two coadministered peptides rather than one engineered multi-agonist molecule. Clinically, the question is the same. Can a second satiety axis raise the efficacy ceiling without an unacceptable tolerability cost?

Safety and Tolerability Context

Across REDEFINE 1 and 2, the safety story tracked the incretin/satiety class. Gastrointestinal adverse events — nausea, vomiting, diarrhea, constipation — were common, more frequent than placebo, and mostly described as mild to moderate and transient during escalation.

That profile is familiar to anyone following GLP-1 medicines. It does not make the combination trivial. Dual appetite suppression can intensify early GI burden, and real-world use always differs from trial titration, support, and selection. Any future labeled product would need the usual clinical framework around contraindications, monitoring, and patient selection rather than consumer self-experimentation.

Cagrilintide and CagriSema remain investigational in the regulatory sense until approvals land. They should not be confused with research-only peptides sold outside clinical channels, nor with compounded products that may claim similar mechanisms without the same manufacturing and trial package.

Where This Fits Next to Existing Options

For readers comparing the current landscape:

• Semaglutide established once-weekly GLP-1 obesity pharmacology at scale.
• Tirzepatide raised the bar with dual GIP/GLP-1 agonism.
• Retatrutide is testing whether adding glucagon pushes mean loss still higher.
• CagriSema asks a different question: what happens if you keep a proven GLP-1 and add a long-acting amylin analogue?

REDEFINE 1’s roughly 20% mean loss puts CagriSema in the same conversation as the strongest late-stage obesity peptides, with the important caveat that cross-trial comparisons are imperfect. Different populations, estimands, and support packages can move numbers by several points.

If you are mapping the commercial and clinical ecosystem rather than the molecules themselves, our provider directory and price index are the practical next stops for what is actually available today versus what is still in phase 3.

Bottom Line

Cagrilintide restored amylin to the center of obesity peptide research. As monotherapy it already reduced weight in phase 2. As CagriSema with semaglutide, it delivered double-digit mean weight loss in diabetes and above 20% mean loss in non-diabetes obesity over 68 weeks in phase 3.

The broader lesson is simple. The next generation of peptide weight-loss medicine is not only about stronger GLP-1 drugs. It is about stacking complementary endocrine signals — incretin, amylin, GIP, glucagon — in combinations the body already uses to control meal size and energy balance. Cagrilintide is the amylin piece of that map.

This article is educational and not medical advice. Discuss any weight-loss medicine, approved or investigational, with a licensed clinician. For foundational context on peptide categories and sourcing literacy, start with Peptides 101 and our experts page.